全文获取类型
收费全文 | 6279篇 |
免费 | 387篇 |
国内免费 | 15篇 |
专业分类
耳鼻咽喉 | 175篇 |
儿科学 | 382篇 |
妇产科学 | 70篇 |
基础医学 | 688篇 |
口腔科学 | 84篇 |
临床医学 | 492篇 |
内科学 | 1414篇 |
皮肤病学 | 139篇 |
神经病学 | 473篇 |
特种医学 | 186篇 |
外科学 | 1057篇 |
综合类 | 57篇 |
一般理论 | 2篇 |
预防医学 | 468篇 |
眼科学 | 129篇 |
药学 | 386篇 |
中国医学 | 5篇 |
肿瘤学 | 474篇 |
出版年
2023年 | 35篇 |
2022年 | 76篇 |
2021年 | 217篇 |
2020年 | 126篇 |
2019年 | 177篇 |
2018年 | 229篇 |
2017年 | 182篇 |
2016年 | 179篇 |
2015年 | 207篇 |
2014年 | 307篇 |
2013年 | 343篇 |
2012年 | 494篇 |
2011年 | 502篇 |
2010年 | 253篇 |
2009年 | 215篇 |
2008年 | 392篇 |
2007年 | 378篇 |
2006年 | 342篇 |
2005年 | 284篇 |
2004年 | 273篇 |
2003年 | 276篇 |
2002年 | 214篇 |
2001年 | 71篇 |
2000年 | 66篇 |
1999年 | 71篇 |
1998年 | 49篇 |
1997年 | 47篇 |
1996年 | 48篇 |
1995年 | 34篇 |
1994年 | 26篇 |
1993年 | 23篇 |
1992年 | 35篇 |
1991年 | 31篇 |
1990年 | 32篇 |
1989年 | 27篇 |
1988年 | 38篇 |
1987年 | 27篇 |
1986年 | 32篇 |
1985年 | 30篇 |
1984年 | 19篇 |
1983年 | 23篇 |
1982年 | 24篇 |
1981年 | 23篇 |
1980年 | 16篇 |
1979年 | 18篇 |
1978年 | 14篇 |
1977年 | 17篇 |
1976年 | 14篇 |
1973年 | 16篇 |
1972年 | 18篇 |
排序方式: 共有6681条查询结果,搜索用时 0 毫秒
41.
From a Pediatric Rheumatology Clinic 361 children diagnosed as juvenile rheumatoid arthritis (JRA) according to American Rheumatism
Association-JRA criteria were studied retrospectively for their clinico-immunological profile. The mean age of onset in systemic,
pauciarticular and polyarticular onset, JRA subtypes were 5.2, 6.8 and 7.2 years respectively. There was male preponderance
in systemic and pauciarticular JRA. In seropositive polyarticular JRA, girls outnumbered boys. The frequency of occurence
of systemic, pauciarticular and polyarticular disease was 87 (24%), 108 (30%) and 166 (46%) respectively. The systemic onset
disease was dominated by extra-articular manifestations in terms of fever (100%), rash (57%), hepatomegaly (51%) and lymphadenopathy
(25%). The pauci- and polyarticular illnesses were commonly dominated by joint involvement, morning stiffness, and in few
patients, by extra-articular manifestations also. The joints were involved symmetrically. Most commonly involved joints in
order of decreasing frequency were knee, ankle, wrist and elbow in all the subtypes. Anemia and leucocytosis were observed
in majority with higher frequency in systemic onset JRA. The rheumatoid factor (RF) was present in 15% of polyarticular JRA.
RF was also present in 7 and 9% of patients with pauciarticular and systemic subtypes respectively. The antinuclear antibody
was positive in only 3 out of 66 patients in whom the test was carried out.
The demographic profile and trends in clinical features were similar to the studies reported on caucasian population with
difference in the actual frequency of various clinical features. 相似文献
42.
Burger A Li H Panayiotakis A Salesiotis A Seth A 《International journal of oncology》1996,8(2):395-400
A number of genes differentially expressed in breast cancer were isolated using a subtractive cloning technique. DNA sequence analysis and GenBank searches of T4F10, T2H7, and T2E5 cDNA clones found them to be identical with E2A, MSS1, and SEC13R genes. Their expression in a variety of primary breast tumor and cancer cell lines was compared with c-ERB-B2 and pS2 by Northern blot analysis. In breast cancer cell lines, the genes that we isolated are more frequently expressed than the previously described c-ERB-B2 and pS2. 相似文献
43.
Deletions in the ligand for CD40 in X-linked immunoglobulin deficiency with normal or elevated IgM (HIGMX-1) 总被引:10,自引:0,他引:10
Ramesh Narayanaswamy; Fuleihan Ramsay; Ramesh Vijaya; Lederman Seth; Yellin Michael J.; Sharma Sunita; Chess Leonard; Rosen Fred S. 《International immunology》1993,5(7):769-773
Patients with X-linked Ig deficiency with normal or elevatedIgM (HIGMX-1) fail to switch from IgM/IgD to other Ig isotypes.Interaction between the B cell antigen CD40 and the CD40 ligandexpressed on activated T cells is critical for T cell drivenisotype switching. We have reported that T lymphocytes fromthree unrelated male patients with HIGMX-1 failed to expressCD40 ligand on their surface, but the mRNA for CD40 ligand wasof an apparently normal size and level. Analysis of CD40 ligandcDNA from two of the patients revealed deletions that alterthe reading frame. Patient 1 displayed two mutations: a C Atransversion at nucleotide 590 and the deletion of an adjacentC nucleotide. The second patient had a 58 bp deletion from nucleotides289–346. Furthermore, neither patient expressed a proteinproduct detectable by the CD40L mAb, 5c8. 相似文献
44.
Glutathione-S-transferase activity has been demonstrated in the brain of rabbit, guinea pig, rat, mouse, and pigeon. The activity was in the following order: rabbit > (guinea pig = mouse) > rat > pigeon. The activity of brain was about 1/3 to 1/9 of that present in liver depending upon the species. In the rat brain glutathione-S-transferase activity was found to be distributed equally in cerebrum, cerebellum, and brain stem and localized mainly in the organelle-free cytosol fraction. 相似文献
45.
Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. 总被引:4,自引:0,他引:4
Jennifer A Low Arlene W Berman Seth M Steinberg David N Danforth Marc E Lippman Sandra M Swain 《Journal of clinical oncology》2004,22(20):4067-4074
PURPOSE: To determine long-term event-free (EFS) and overall survival (OS) for patients with stage III breast cancer treated with combined-modality therapy. PATIENTS AND METHODS: Between 1980 and 1988, 107 patients with stage III breast cancer were prospectively enrolled for study at the National Cancer Institute and stratified by whether or not they had features of inflammatory breast cancer (IBC). Patients were treated to best response with cyclophosphamide, doxorubicin, methotrexate, fluorouracil, leucovorin, and hormonal synchronization with conjugated estrogens and tamoxifen. Patients with pathologic complete response received definitive radiotherapy to the breast and axilla, whereas patients with residual disease underwent mastectomy, lymph node dissection, and radiotherapy. All patients underwent six additional cycles of adjuvant chemotherapy. RESULTS: OS and EFS were obtained with a median live patient follow-up time of 16.8 years. The 46 IBC patients had a median OS of 3.8 years and EFS of 2.3 years, compared with 12.2 and 9.0 years, respectively, in stage IIIA breast cancer patients. Fifteen-year OS survival was 20% for IBC versus 50% for stage IIIA patients and 23% for stage IIIB non-IBC. Pathologic response was not associated with improved survival for stage IIIA or IBC patients. Presence of dermal lymphatic invasion did not change the probability of survival in clinical IBC patients. CONCLUSION: Fifteen-year follow-up of stage IIIA and inflammatory breast cancer is rarely reported; IBC patients have a poor long-term outlook. 相似文献
46.
Antoinette R Tan Xiaowei Yang Stephen M Hewitt Arlene Berman Erin R Lepper Alex Sparreboom Allyson L Parr William D Figg Catherine Chow Seth M Steinberg Stephen L Bacharach Millie Whatley Jorge A Carrasquillo Jaime S Brahim Seth A Ettenberg Stan Lipkowitz Sandra M Swain 《Journal of clinical oncology》2004,22(15):3080-3090
PURPOSE: To evaluate changes in epidermal growth factor receptor (EGFR) phosphorylation and its downstream signaling in tumor and surrogate tissue biopsies in patients with metastatic breast cancer treated with erlotinib, an EGFR tyrosine kinase inhibitor, and to assess relationships between biomarkers in tumor and normal tissues and between biomarkers and pharmacokinetics. PATIENTS AND METHODS: Eighteen patients were treated orally with 150 mg/d of erlotinib. Ki67, EGFR, phosphorylated EGFR (pEGFR), phosphorylated mitogen-activated protein kinase (pMAPK), and phosphorylated AKT (pAKT) in 15 paired tumor, skin, and buccal mucosa biopsies (at baseline and after 1 month of therapy) were examined by immunohistochemistry and analyzed quantitatively. Pharmacokinetic sampling was also obtained. RESULTS: The stratum corneum layer and Ki67 in keratinocytes of the epidermis in 15 paired skin biopsies significantly decreased after treatment (P = .0005 and P = .0003, respectively). No significant change in Ki67 was detected in 15 tumors, and no responses were observed. One was EGFR-positive and displayed heterogeneous expression of the receptor, and 14 were EGFR-negative. In the EGFR-positive tumor, pEGFR, pMAPK, and pAKT were reduced after treatment. Paradoxically, pEGFR was increased in EGFR-negative tumors post-treatment (P = .001). Although markers were reduced in surrogate and tumor tissues in the patient with EGFR-positive tumor, no apparent associations were observed in patients with EGFR-negative tumor. CONCLUSION: Erlotinib has inhibitory biologic effects on normal surrogate tissues and on an EGFR-positive tumor. The lack of reduced tumor proliferation may be attributed to the heterogeneous expression of receptor in the EGFR-positive patient and absence of target in this cohort of heavily pretreated patients. 相似文献
47.
Gerald E Hanks Thomas F Pajak Arthur Porter David Grignon Harmart Brereton Varagur Venkatesan Eric M Horwitz Colleen Lawton Seth A Rosenthal Howard M Sandler William U Shipley 《Journal of clinical oncology》2003,21(21):3972-3978
PURPOSE: Radiation Therapy Oncology Group (RTOG) Protocol 92-02 was a randomized trial testing long-term (LT) adjuvant androgen deprivation (AD) after initial AD with external-beam radiotherapy (RT) in patients with locally advanced prostate cancer (PC; T2c-4) and with prostate-specific antigen level less than 150 ng/mL. PATIENTS AND METHODS: Patients received a total of 4 months of goserelin and flutamide, 2 months before and 2 months during RT. A radiation dose of 65 to 70 Gy was given to the prostate and a dose of 44 to 50 Gy to the pelvic lymph nodes. Patients were randomly assigned to receive no additional therapy (short-term [ST]AD-RT) or 24 months of goserelin (LTAD-RT); 1,554 patients were entered onto the study. RESULTS: The LTAD-RT arm showed significant improvement in all efficacy end points except overall survival (OS; 80.0% v 78.5% at 5 years, P =.73), compared with the STAD-RT arm. In a subset of patients not part of the original study design, with tumors assigned Gleason scores of 8 to 10 by the contributing institutions, the LTAD-RT arm had significantly better OS (81.0% v 70.7%, P =.044). There was a small but significant increase in the frequency of late radiation grades 3, 4, and 5 gastrointestinal toxicity ascribed to the LTAD-RT arm (2.6% v 1.2% at 5 years, P =.037), the cause of which is not clear. CONCLUSION: The RTOG 92-02 trial supports the addition of LT adjuvant AD to STAD with RT for T2c-4 PC. In the exploratory subset analysis of patients with Gleason scores 8 to 10, LT adjuvant AD resulted in a survival advantage. 相似文献
48.
49.
Uterine thermal balloon therapy for the treatment of menorrhagia: the first 300 patients from a multi-centre study 总被引:6,自引:0,他引:6
Nazar N. Amso Consultant Seth A. Stabinsky Clinical Assistant Professor/Associate Medical Director †‡ Peter McFaul Consultant Bernard Blanc Professor †† Laura Pendley Manager ‡ Robert Neuwirth Professor/Chairman Emeritus § 《BJOG : an international journal of obstetrics and gynaecology》1998,105(5):517-523
50.